Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Skyrizi (risankizumab-rzaa) for the Treatment of Plaque Psoriasis

Drug Name

Skyrizi™ (risankizumab-rzaa)

Developers

Boehringer Ingelheim and AbbVie

Therapy Class

Monoclonal antibody

Product Description

Selective Interleukin-23 (IL-23) inhibitor

Current Indication

Plaque psoriasis

Market Sector

Dermatology

Development Status

Approved in the US, Canada, Europe, and Japan
Expand
Close
Close
Close

Go Top